Literature DB >> 8890452

Neurotoxicity induced by interleukin-2: involvement of infiltrating immune cells.

U K Hanisch1, J Neuhaus, R Quirion, H Kettenmann.   

Abstract

Interleukin-2 (IL-2), a key regulator of immune functions, also has potent effects on neurons and glia. IL-2 modulates neural cell growth and survival and transmitter and hormone releases and is thought to mediate neuroimmune interactions. Investigating the neuroendocrine consequences of chronically elevated central nervous system (CNS) levels of IL-2, we recently observed marked neurotoxicity [Hanisch et al. (1994) Endocrinology 135:2465-2472]. In the present study, we characterize in detail the modifications in brain tissue architecture as they result in Sprague-Dawley rats from intracerebroventricular (i.c.v.) administration of low amounts of IL-2 (5 and 15 U/h, respectively, delivered by means of osmotic minipumps for up to 14 days). Histological inspection of the brains revealed massive cellular infiltrates in the ipsilateral hemisphere. The infiltrates were associated with pronounced angiogenesis and changes in the composition of the extracellular matrix. These anatomical changes apparently developed between day 7 and 14. They were specific for IL-2 and were not seen in animals treated, for example, with heat-inactivated IL-2 (controls). We further show that chronic central administration of IL-2 let to T and B lymphocyte invasion of the brain and an intracranial agglomeration of large numbers of MHC class II-positive cells. Immunocytochemistry revealed a widespread inundation of CNS tissue and a decoration of glial cells and neurons by endogenous antibodies. Tissue regions around the IL-2-induced infiltrates showed myelin destruction and neuronal cell loss. Chronically elevated CNS levels of IL-2 may, thus, not only interfere with neurotransmission and endocrine functions but also severely disturb tissue homeostasis. Therefore, the present findings could be relevant to brain injuries, CNS disorders, and clinical treatments associated with increased IL-2 levels or involving an immune component.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890452     DOI: 10.1002/(SICI)1098-2396(199610)24:2<104::AID-SYN2>3.0.CO;2-J

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

2.  Loss of Neuronal Phenotype and Neurodegeneration: Effects of T Lymphocytes and Brain Interleukin-2.

Authors:  Danielle Meola; Zhi Huang; Grace K Ha; John M Petitto
Journal:  J Alzheimers Dis Parkinsonism       Date:  2013-06

3.  Sensitization to brain antigens after stroke is augmented by lipopolysaccharide.

Authors:  Kyra J Becker; Darin L Kindrick; Mark P Lester; Connor Shea; Zu-Cheng Ye
Journal:  J Cereb Blood Flow Metab       Date:  2005-12       Impact factor: 6.200

Review 4.  Sensitization and tolerization to brain antigens in stroke.

Authors:  K J Becker
Journal:  Neuroscience       Date:  2008-07-25       Impact factor: 3.590

5.  Low cerebral blood flow is a non-invasive biomarker of neuroinflammation after repetitive mild traumatic brain injury.

Authors:  Sitara B Sankar; Alyssa F Pybus; Amanda Liew; Bharat Sanders; Kajol J Shah; Levi B Wood; Erin M Buckley
Journal:  Neurobiol Dis       Date:  2018-12-25       Impact factor: 5.996

6.  Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Authors:  Brendan Curti; Gregory A Daniels; David F McDermott; Joseph I Clark; Howard L Kaufman; Theodore F Logan; Jatinder Singh; Meenu Kaur; Theresa L Luna; Nancy Gregory; Michael A Morse; Michael K K Wong; Janice P Dutcher
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.